ANIP - ANI Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANIP is currently covered by 4 analysts with an average price target of $78.74. This is a potential upside of $16.44 (26.39%) from yesterday's end of day stock price of $62.3.

ANI Pharmaceuticals's activity chart (see below) currently has 60 price targets and 63 ratings on display. The stock rating distribution of ANIP is 91.67% BUY and 8.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 79.54% with an average time for these price targets to be met of 338.13 days.

Highest price target for ANIP is $94, Lowest price target is $62, average price target is $81.25.

Most recent stock forecast was given by VAMIL DIVAN from GUGGENHEIM on 11-Apr-2025. First documented stock forecast 14-Dec-2014.

Currently out of the existing stock ratings of ANIP, 22 are a BUY (91.67%), 2 are a HOLD (8.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$86

$19.7 (29.71%)

$86

1 months 2 days ago
(11-Apr-2025)

6/9 (66.67%)

$17.88 (26.25%)

343

Buy

$94

$27.7 (41.78%)

$94

1 months 26 days ago
(17-Mar-2025)

4/13 (30.77%)

$29.65 (46.08%)

148

Hold

$62

$-4.3 (-6.49%)

$60

6 months 21 days ago
(22-Oct-2024)

8/9 (88.89%)

$1.92 (3.20%)

396

Buy

$83

$16.7 (25.19%)

$49

7 months 25 days ago
(18-Sep-2024)

10/12 (83.33%)

$21.95 (35.95%)

474

Hold

$42

$-24.3 (-36.65%)

$40

2 years 5 days ago
(08-May-2023)

2/3 (66.67%)

$-0.58 (-1.36%)

274

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANIP (ANI Pharmaceuticals) average time for price targets to be met?

On average it took 338.13 days on average for the stock forecasts to be realized with a an average price target met ratio 79.54

Which analyst has the current highest performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

LOUISE CHEN

Which analyst has the current lower performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

BRANDON FOLKES

Which analyst has the most public recommendations on ANIP (ANI Pharmaceuticals)?

Louise Chen works at SCOTIABANK and has 9 price targets and 5 ratings on ANIP

Which analyst is the currently most bullish on ANIP (ANI Pharmaceuticals)?

Oren Livnat with highest potential upside - $27.7

Which analyst is the currently most reserved on ANIP (ANI Pharmaceuticals)?

Brandon Folkes with lowest potential downside - -$24.3

ANI Pharmaceuticals in the News

Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the consensus of $1.38 per share. The company reported sales of $197.12 million, up 43.4% year over year, beating the consensus of $180.68 million. On an organic basis, excluding the acquisition of Alimera, total...

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

ANI Pharmaceuticals (ANIP) reported $197.12 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 43.4%. EPS of $1.70 for the same period compares to $1.21 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $179.45 million, representing a surprise of +9.85%. The company delivered an EPS...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?